Rotational and Directional Atherectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Atherectomy is a minimally invasive, catheter-based technique that physically removes atherosclerotic plaque from the inner walls of arteries rather than simply compressing it (as angioplasty does) or bypassing the blockage surgically. Two principal modalities are widely used in clinical practice:

Rotational Atherectomy (RA) — also known as rotablation — employs a diamond-coated burr rotating at 140,000–180,000 revolutions per minute to abrade and pulverise calcified plaque into micro-particles (less than 10 microns in diameter) small enough to be cleared by the reticuloendothelial system. It is primarily used in heavily calcified coronary lesions that cannot be adequately dilated with conventional balloon angioplasty, facilitating stent expansion and apposition.

Directional Coronary Atherectomy (DCA) uses a cutting device with a side window and rotating cutter to selectively excise and retrieve plaque, allowing the operator to target specific quadrants of eccentric lesions. While largely superseded by drug-eluting stents in coronary intervention, directional atherectomy retains an important role in peripheral vascular disease, particularly for below-the-knee and superficial femoral artery lesions where stent placement is less desirable.

Both techniques are complementary to stenting and are typically used as lesion-preparation strategies to ensure optimal stent delivery and long-term patency.

Atherectomy devices address arterial disease characterised by severe calcification, fibrosis, or in-stent restenosis:

• Severely calcified coronary artery disease: Rotational atherectomy is the primary tool for de-bulking heavily calcified coronary stenoses — classified as moderate-to-severe on intravascular imaging (IVUS or OCT) — prior to stent implantation. Calcium prevents adequate balloon dilation and impairs stent expansion.
• In-stent restenosis (ISR): Recurrent narrowing within previously placed coronary stents (particularly due to neointimal hyperplasia) that cannot be managed with balloon angioplasty alone.
• Peripheral artery disease (PAD): Directional and orbital atherectomy devices are extensively used for superficial femoral artery (SFA), popliteal artery, and infrapopliteal vessel disease causing claudication or critical limb ischaemia.
• Chronic total occlusions (CTOs): Rotablation may facilitate crossing of complex, calcified total occlusions after wire crossing has been achieved.
• Ostial lesions: Directional atherectomy is well suited to ostial coronary or renal artery lesions where stent protrusion into the parent vessel is undesirable.

Atherectomy is not suitable for all patients with arterial disease. Appropriate candidacy is determined by a combination of clinical, anatomical, and procedural factors:

• Anatomical suitability: Moderate-to-severe coronary calcification confirmed on intravascular imaging (IVUS/OCT) or fluoroscopy. Peripheral lesions with heavy calcium burden or fibrosis that resist balloon dilation.
• Symptom burden: Patients with stable angina, acute coronary syndromes (selected cases), or peripheral ischaemia (claudication, rest pain, tissue loss) refractory to medical therapy.
• Coronary anatomy: Reference vessel diameter ≥2.0 mm for coronary rotablation. Very tortuous vessels, extreme angulation at the lesion, or massive thrombus burden are relative contraindications.
• Peripheral disease: Patients with symptomatic PAD (Rutherford class 2–6) who have failed or are not candidates for surgical bypass.
• Renal function: Adequate renal reserve to tolerate contrast agent; pre-hydration and contrast minimisation strategies are employed in patients with chronic kidney disease.
• Antiplatelet compliance: All patients must be able to take dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) peri-procedurally and for 1–6 months post-stenting.

Rotational Atherectomy (Coronary):

1. Vascular access is obtained via the femoral or radial artery under local anaesthesia. A guiding catheter is positioned at the coronary ostium.
2. A specialised rotablation guidewire is advanced across the lesion under fluoroscopic guidance.
3. Burr selection (typically 1.25–2.0 mm) is based on reference vessel diameter, targeting a burr-to-artery ratio of 0.5–0.7.
4. The rotating burr is advanced through the calcified lesion in short, controlled passes (15–20 seconds), pulverising calcium into microscopic particles.
5. Following adequate lesion modification, conventional balloon angioplasty and drug-eluting stent implantation are performed with intravascular imaging guidance to confirm full stent expansion.

Directional Atherectomy (Peripheral):

1. Arterial access is gained, typically from the contralateral femoral artery for femoral-popliteal disease.
2. The directional atherectomy catheter (e.g., SilverHawk or TurboHawk device) is advanced to the lesion under fluoroscopic guidance.
3. The rotating blade excises plaque in directional passes; excised material is collected in the nose cone of the catheter and removed.
4. Multiple passes are made to achieve circumferential plaque removal. Drug-coated balloon angioplasty is commonly applied afterwards to reduce restenosis.

Adjunctive pharmacotherapy during the procedure includes intravenous unfractionated heparin for anticoagulation, intracoronary nitrates and calcium channel blockers (for rotablation) to prevent vasospasm, and platelet glycoprotein IIb/IIIa inhibitors in selected high-risk cases.

• Enables treatment of otherwise untreatable lesions: Severely calcified arteries that resist conventional balloon dilation can be successfully treated with atherectomy, expanding the spectrum of patients suitable for percutaneous revascularisation and avoiding surgical bypass.
• Improved stent expansion and apposition: By modifying calcified plaque prior to stenting, atherectomy facilitates full stent expansion, reducing the risk of stent under-expansion and associated adverse events (stent thrombosis, restenosis).
• Minimally invasive approach: Performed via a small arterial puncture under local anaesthesia, avoiding the morbidity of open surgical revascularisation, particularly valuable in elderly or high-risk patients.
• Rapid recovery: Most patients are discharged within 24 hours; return to normal activities within 1–2 weeks is typical.
• Limb salvage in PAD: Directional atherectomy combined with drug-coated balloon therapy achieves high rates of primary patency in below-the-knee vessels, contributing to limb salvage in critical limb-threatening ischaemia (CLTI).
• Plaque removal vs. compression: Unlike balloon angioplasty, atherectomy physically removes plaque, reducing elastic recoil and potentially improving long-term lumen dimensions.

Both rotational and directional atherectomy carry risks specific to the technique in addition to standard catheterisation risks:

• Slow flow / no-reflow: Particulate debris from atherectomy can embolise distally, obstructing microvasculature and causing transient or permanent reduction in coronary blood flow (approximately 5–10% in rotablation). Intracoronary vasodilators are given prophylactically.
• Coronary perforation: Perforation of the coronary artery wall is a rare but potentially life-threatening complication (approximately 0.5–1.5%) requiring urgent pericardiocentesis or surgery if tamponade develops.
• Dissection: Atherectomy may create or propagate vessel dissections, complicating subsequent stent placement.
• Burr entrapment (rotablation): Rare mechanical entrapment of the rotating burr within a tight stenosis requiring specialised extraction techniques.
• Distal embolisation (peripheral): Debris from directional atherectomy in peripheral vessels can embolise to distal limb arteries, requiring aspiration thrombectomy or surgical embolectomy.
• Vascular access complications: Haematoma, pseudoaneurysm, or arteriovenous fistula at the arterial puncture site (1–3%).
• Renal impairment: Contrast-induced nephropathy, particularly in patients with pre-existing chronic kidney disease.
• Restenosis: Despite plaque removal, neointimal hyperplasia can lead to in-segment restenosis, necessitating repeat intervention in 10–20% of cases at 12 months.

Immediate post-procedure: Patients are monitored in a recovery ward for 4–6 hours after femoral access cases, or 1–2 hours for transradial cases. Bed rest is required until arterial access haemostasis is confirmed. ECG monitoring and serial troponin measurements are performed after coronary atherectomy.

Discharge and first 2 weeks: Most patients are discharged within 24 hours. The puncture site should be kept dry and inspected daily; patients should report any bleeding, swelling, or limb discolouration. Strenuous physical activity and heavy lifting are restricted for 1 week.

Antiplatelet therapy: Dual antiplatelet therapy (aspirin plus clopidogrel, prasugrel, or ticagrelor) is mandatory after coronary stent implantation, typically for 6–12 months. For peripheral atherectomy without stenting, aspirin monotherapy is standard.

Longer-term surveillance:

• Coronary disease: Stress testing or coronary CT angiography at 12 months if symptomatic. Annual cardiology review.
• Peripheral disease: Ankle-brachial index (ABI) measurement and duplex ultrasound at 1, 6, and 12 months to assess patency. Wound review in critical limb ischaemia patients.

Smoking cessation, statin therapy, blood pressure control, and diabetic management are essential to slow disease progression and reduce restenosis risk.

The cost of atherectomy procedures is substantially higher than standard balloon angioplasty due to the specialised single-use devices involved:

• Device costs: Rotablation burrs and directional atherectomy catheters are single-use, high-cost disposables (USD 1,500–4,000 per device). These dominate the incremental cost above standard PCI.
• Country of treatment: Total procedural costs range from USD 3,000–8,000 in India and Thailand to USD 25,000–60,000 in the United States. European centres typically cost USD 10,000–20,000.
• Additional stenting: Drug-eluting stents (USD 800–2,500 each) are usually implanted after coronary rotablation, adding to total cost.
• Hospital setting: Procedures in dedicated cardiac catheterisation laboratories at accredited hospitals with on-site cardiac surgery backup are costlier but considerably safer.
• Complexity: Multivessel coronary disease or lengthy peripheral artery lesions requiring multiple atherectomy passes significantly increase procedure time and device utilisation.
• Insurance coverage: In many countries, atherectomy is covered by health insurance when guideline criteria are met (e.g., severely calcified lesions). Patients should verify coverage prior to elective procedures.

• Balloon angioplasty (PTCA): Standard balloon dilation is the first-line endovascular approach for most coronary and peripheral lesions; atherectomy is reserved for calcified or resistant lesions where balloons fail or under-expand.
• Drug-eluting stents (DES): Coronary stenting alone is the standard of care for most coronary lesions. In calcified lesions, atherectomy serves as lesion modification prior to DES, not an alternative.
• Drug-coated balloons (DCB): Paclitaxel-coated or sirolimus-coated balloons are used in combination with atherectomy for peripheral vascular disease, particularly in small vessels where stenting is unfavourable.
• Intravascular lithotripsy (IVL): A newer modality that uses sonic pressure waves to fracture calcified plaque via an angioplasty-style catheter. Gaining traction as an alternative or adjunct to rotablation for coronary calcification.
• Coronary artery bypass grafting (CABG): Open-heart bypass surgery remains the gold standard for complex multivessel or left main coronary disease with high SYNTAX scores, particularly in diabetic patients. Preferred over percutaneous approaches in such anatomy.
• Surgical bypass (peripheral): For critical limb ischaemia or long-segment occlusions unsuitable for endovascular treatment, femoral-popliteal or femoral-tibial bypass provides durable revascularisation.